Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

West Nile virus disease therapeutics : review of the literature for healthcare providers
  • Published Date:

    June 15, 2015

  • Language:
Filetype[PDF-200.21 KB]

  • Description:
    Revised June 15,2015 No antiviral or adjunctive therapies are approved or recommended for the treatment of West Nile virus (WNV) disease; clinical management is supportive. There are numerous case reports and case series regarding the use of various products (e.g., standard and hyperimmune polyclonal immune globulin, monoclonal immune globulin, interferon, ribavirin, and corticosteroids) in patients with WNV disease. Several of these products have been studied in controlled clinical trials for infections due to WNV or closely related flaviruses (i.e., St. Louis encephalitis and Japanese encephalitis viruses). None have shown benefit. However, the studies often had small sample sizes and the results from some of the clinical trials have not been published. Since polyclonal immune globulin and interferon alpha-n3 are available, some physicians have chosen to use them to treat transplant recipients and other severely immunocompromised patients but there is no proven benefit. WNV-therapeutics-summary.pdf
  • Main Document Checksum:
  • File Type:
  • Supporting Files:
    No Additional Files
No Related Documents.

You May Also Like: